Merck (MRK) and Moderna (MRNA) announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940, an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk melanoma. Global recruitment in V940-001 has begun, and the first patients are now enrolling in Australia.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- VTI ETF’s Simple but Powerful Strategy is a Long-Term Winner
- Merck announces CHMP opinion recommending approval of gefapixant
- Merck announces CHMP opinion recommending approval of Keytruda
- Pfizer price target lowered to $42 from $43 at Morgan Stanley
- Merck price target lowered to $116 from $118 at Truist